Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +15

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Jenn‐Yu Wu, Chong‐Jen Yu, Yeun‐Chung Chang et al. · Clinical Cancer Research · 2011 · 466 citations · Full text

Medicine, Oncology, Pharmacology +14

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Jenn‐Yu Wu, Shang‐Gin Wu, Chien‐Hung Gow et al. · Clinical Cancer Research · 2008 · 322 citations · Full text

Medicine, Oncology, Pharmacology +13

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

Tommaso De Pas, Francesca Toffalorio, Michela Manzotti et al. · Journal of Thoracic Oncology · 2011 · 141 citations · Full text

Medicine, Oncology, Pharmacology +10